The Online Investor

Slideshow Stock Splits

By The Online Investor Staff, updated Tue., May. 24, 9:02 AM

Slide #6. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) 1 for 32 Reverse Split

Announced: 5/16/2022
Stock Split: 1 for 32
Record Date: 5/16/2022
Pay Date: 5/17/2022
TNXP Optionable?: No

Tonix Pharmaceuticals Holding is a clinical-stage biopharmaceutical company focused on discovering, cquiring and developing therapeutics and diagnostics to treat and prevent human disease. Co.'s portfolio is primarily composed of immunology, central nervous system (CNS), and infectious disease product candidates. Co.'s key product candidate within its immunology pipeline is TNX-1500, a humanized monoclonal antibody, directed against CD40-ligand, engineered to modulate binding to Fc receptors, that is being developed as a prophylaxis against organ transplant rejection. Among the CNS candidates in development is TNX-1300 which is for the treatment of life-threatening cocaine intoxication.

TNXP SEC Filing Email Alerts Service

TNXP Detailed Information Page & Split History »

Company Name: 
Tonix Pharmaceuticals Holding Corp
Stock buyback: 
TNXP buyback
Website: 
www.tonixpharma.com;www.tonix.com;www.krele.com
Sector: 
Biotechnology
Number of ETFs Holding TNXP: 
7
Total Market Value Held by ETFs: 
$6.17B
Total Market Capitalization: 
$41.00M
% of Market Cap. Held by ETFs: 
15044.73%

Open the TNXP Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree TNXP Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
69th percentile
(ranked higher than approx. 69% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Stock Splits Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.